尿路上皮がんに重点を置いた進行性固形腫瘍に対する通常の化学療法治療(シスプラチン、またはシスプラチンとゲムシタビン)への抗がん剤 BAY 1895344 の追加の試験
尿路上皮癌に重点を置いた進行性固形腫瘍におけるATR阻害剤BAY 1895344とシスプラチンおよびシスプラチンとゲムシタビンの併用の第1相試験
This phase I trial identifies the best dose, possible benefits and/or side effects of BAY 1895344 in combination with chemotherapy in treating patients with solid tumors or urothelial cancer that has spread to other places in the body (advanced). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cisplatin and gemcitabine are chemotherapy drugs that stop the growth of tumor cells by killing the cells. Combining BAY 1895344 with chemotherapy treatment (cisplatin, or cisplatin and gemcitabine) may be effective for the treatment of advanced solid tumors, including urothelial cancer.
調査の概要
状態
条件
- 解剖学的ステージ III 乳がん AJCC v8
- 解剖学的ステージ IV 乳がん AJCC v8
- 進行性悪性固形新生物
- ステージ III 肺がん AJCC v8
- ステージ IV 肺がん AJCC v8
- 臨床病期 III の胃がん AJCC v8
- 臨床病期 IV 胃がん AJCC v8
- トリプルネガティブ乳がん
- ステージ IV 陰茎がん AJCC v8
- 進行性胃がん
- 進行性乳癌
- ステージ III 子宮頸がん AJCC v8
- ステージ IV 子宮頸がん AJCC v8
- 進行性肺非小細胞がん
- ステージ III 卵巣がん AJCC v8
- ステージ IV 卵巣がん AJCC v8
- 進行性卵巣癌
- 切除不能な尿路上皮がん
- 進行性頭頸部がん
- 進行性肺小細胞がん
- 進行性尿路上皮がん
- ステージ IV 遠位胆管がん AJCC v8
- ステージ IV 肝内胆管がん AJCC v8
- 進行性食道癌
- 進行した子宮内膜がん
- 進行性胸膜悪性中皮腫
- ステージ III 遠位胆管がん AJCC v8
- 進行性胆管がん
- 進行性子宮頸がん
- 進行性陰茎がん
- III期の肝内胆管がんAJCC v8
- III期の陰茎がん AJCC v8
- ステージIII 胸膜びまん性悪性中皮腫 AJCC v8
- ステージIV 胸膜びまん性悪性中皮腫 AJCC v8
詳細な説明
PRIMARY OBJECTIVES:
I. To establish the safety and tolerability of the combination of cisplatin + elimusertib (BAY 1895344) in patients with advanced solid tumors.
II. To establish the safety and tolerability of the combination of cisplatin + gemcitabine + BAY 1895344 in patients with advanced solid tumors with an emphasis on urothelial carcinoma (UC).
III. To establish the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of cisplatin + BAY 1895344 and cisplatin + gemcitabine + BAY 1895344.
SECONDARY OBJECTIVES:
I. To evaluate the pharmacokinetic profile of BAY 1895344 (in the doublet and triplet combinations) and gemcitabine (in the triplet) in combination with cisplatin.
II. To further evaluate the toxicity of the combination of cisplatin + gemcitabine + BAY 1895344 in patients with UC.
III. To evaluate preliminary efficacy observed with cisplatin + BAY 1895344 and cisplatin + gemcitabine + BAY 1895344 in patients with advanced solid tumors, including UC.
EXPLORATORY OBJECTIVES:
I. To evaluate the correlation of biomarkers, including deleterious deoxyribonucleic acid (DNA) damage response (DDR) gene alterations and circulating tumor (ct)DNA with responses to therapy using whole exome sequencing (WES) and messenger ribonucleic acid sequencing (RNA seq) analysis of archival formalin fixed paraffin embedded (FFPE) tissue, as well as blood.
II. To correlate drug exposure with response and/or toxicity.
OUTLINE: This is a dose-escalation study of elimusertib. Patients are assigned to 1 of 2 arms.
ARM I (DOUBLET COMBINATION): Patients receive cisplatin intravenously (IV) over 1-2 hours on day 1 and 8, and elimusertib orally (PO) once daily (QD) on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
ARM II (TRIPLET COMBINATION): Patients receive cisplatin IV over 1-2 hours on day 1 and 8, gemcitabine IV over 30 minutes on days 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, then every 3 months thereafter.
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究場所
-
-
California
-
Sacramento、California、アメリカ、95817
- University of California Davis Comprehensive Cancer Center
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20892
- National Institutes of Health Clinical Center
-
Bethesda、Maryland、アメリカ、20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
New York
-
New York、New York、アメリカ、10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
Ohio
-
Columbus、Ohio、アメリカ、43210
- Ohio State University Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15232
- UPMC Hillman Cancer Center
-
-
Wisconsin
-
Madison、Wisconsin、アメリカ、53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
-
-
-
Ontario
-
Toronto、Ontario、カナダ、M5G 2M9
- University Health Network-Princess Margaret Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Histologically-confirmed advanced solid tumor with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 criteria, for which cisplatin-based therapy would be considered appropriate, including:
- Non-small cell lung cancer (NSCLC)
- UC
- Penile cancer
- Malignant pleural mesothelioma
- Small cell lung cancer
- Biliary tract cancer
- Esophageal and gastric cancers
- Ovarian cancer
- Endometrial cancer
- Cervical cancer
- Head and neck cancer
- Triple-negative breast cancer (Her2/neu-negative, estrogen receptor [ER]/progesterone receptor [PR]-negative breast cancer)
-
For the expansion cohort of the triplet combination at MTD/RP2D only:
- Patients with histologically confirmed advanced or unresectable urothelial carcinoma are eligible
- The histology should be predominantly urothelial (>= 50% of sample evaluated contains urothelial histology)
-
Age >= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 in combination with gemcitabine and cisplatin in patients < 18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Availability of archival FFPE tissue
-
Prior cisplatin exposure of < 300 mg/m^2. Patients with prior cisplatin treatment must have received last cisplatin treatment > 6 months prior to enrollment
-
Prior treatment with PARP inhibitors is permitted (such as olaparib, rucaparib, or other experimental inhibitors of PARP administered in a clinical trial)
-
Prior immune checkpoint inhibitor therapy is permitted (including anti-programmed cell death protein 1 [PD-1], anti-PD-ligand [L]1 therapy, such as pembrolizumab, nivolumab, avelumab, durvalumab, atezolizumab, or anti-cytotoxic t-lymphocyte protein 4 [CTLA4] therapy such as ipilimumab, or other experimental immune checkpoint pathway inhibitors administered in a clinical trial)
-
Leukocytes >= 3,000/mcL
-
Hemoglobin >= 9 g/dL
-
Neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Total bilirubin =< 2 mg/dL
-
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 3 x institutional upper limit of normal (ULN)
-
Creatinine clearance >= 40 mL/min OR glomerular filtration rate (GFR) >= 40 mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy; patients with stable brain metastases that are asymptomatic and on a stable dose of steroids are also considered eligible
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional classification. To be eligible for this trial, patients should be class 2B or better
-
The effects of BAY 1895344, cisplatin, and gemcitabine on the developing human fetus are unknown. For this reason and because deoxyribonucleic acid (DNA)-damage response inhibitors agents as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of BAY 1895344 administration
-
Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
- Life expectancy < 6 weeks by investigator assessment
- Other active malignancy requiring treatment, except for cutaneous malignancies that require resection such as squamous cell carcinoma, basal cell carcinoma, or cutaneous melanoma, and except for prostate cancer if only on androgen deprivation therapy
- Significant peripheral neuropathy (grade 2 or higher by Common Terminology Criteria for Adverse Events [CTCAE])
- Sensorineural hearing loss (grade 2 or higher by CTCAE)
- Must NOT have had prior treatment with ATR inhibitor (prior BAY1895344 or other investigational ATR inhibitors), or current treatment with any other investigational agents
- Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Patients who have targeted therapies (such as PARP inhibitors) within 2 weeks prior to entering the study
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344 or other agents used in study
- Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window, or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor, cisplatin, and gemcitabine may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm I (cisplatin, elimusertib)
Patients receive cisplatin IV over 1-2 hours on day 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given PO
他の名前:
|
|
実験的:Arm II (cisplatin, gemcitabine, elimusertib)
Patients receive cisplatin IV over 1-2 hours on day 1 and 8, gemcitabine IV over 30 minutes on days 1 and 8, and elimusertib PO QD on days 2 and 9. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. |
Given IV
他の名前:
Given IV
他の名前:
Given PO
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
BAY 1895344 の第 2 相推奨用量(RP2D)
時間枠:治療開始日から21日以内
|
治療開始日から21日以内
|
|
|
Incidence of adverse events
時間枠:Up to 28 days after completion of study treatment
|
Toxicities will be tabulated and reported according to dose level, grade, type, cycle, and attribution. Tables will be created to summarize these toxicities and side effects, overall and by cohort. Proportions and associated 95% confidence intervals will be calculated for each cohort separately. Cumulative incidence curves will be used to estimate the proportion of patients who will discontinue therapy for reasons of toxicity or general inability to tolerate the regimen. |
Up to 28 days after completion of study treatment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Pharmacokinetic (PK) parameter - maximum concentration (Cmax)
時間枠:Day 2 and day 9 after treatment start date
|
Estimated using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data (gemcitabine). |
Day 2 and day 9 after treatment start date
|
|
PK parameter - area under the concentration-time curve (AUC)
時間枠:Day 2 and day 9 after treatment start date
|
Estimated using non-compartmental methods. The PK variables will be tabulated and descriptive statistics (e.g., geometric means and coefficients of variation) calculated for each dose level. PK parameters will be reported descriptively for exploratory comparison with historical data (gemcitabine). The impact of cisplatin on BAY 1895344 exposure will be evaluated by calculation of the AUC ratio of (day 9 / day 2) and testing non-parametrically with a null hypothesis of a ratio = 1. |
Day 2 and day 9 after treatment start date
|
|
Deoxyribonucleic acid (DNA) damage repair (DDR) mutations
時間枠:Up to 2 years
|
The association between DDR mutations and responses will be described, with a table outlining patients who achieved by progressive disease, stable disease, partial or complete responses and DDR mutation status. |
Up to 2 years
|
|
Response rate
時間枠:Up to 2 years
|
The percent of responders will be calculated and associated exact 95% confidence intervals will be constructed. |
Up to 2 years
|
|
Progression-free survival (PFS)
時間枠:Up to 2 years
|
Kaplan-Meier plots will be used to summarize PFS. |
Up to 2 years
|
協力者と研究者
捜査官
- 主任研究者:Mamta Parikh、City of Hope Comprehensive Cancer Center LAO
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 泌尿生殖器疾患
- 生殖器疾患
- 内分泌系疾患
- 性器腫瘍、男性
- 泌尿生殖器腫瘍
- 部位別新生物
- 新生物
- 生殖器疾患、男性
- 男性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患
- 女性の泌尿生殖器疾患と妊娠合併症
- 気道疾患
- 組織型別の新生物
- 子宮の病気
- 生殖器疾患、女性
- 肺疾患
- 内分泌腺腫瘍
- 新生物、腺および上皮
- 気道腫瘍
- 胸部腫瘍
- 卵巣疾患
- 付属器疾患
- 性器腫瘍、女性
- 性腺疾患
- 腺腫
- 新生物、中皮
- 胸膜腫瘍
- 皮膚疾患
- 乳房の病気
- 子宮頸部疾患
- 子宮腫瘍
- 乳房腫瘍
- 陰茎の病気
- 皮膚および結合組織疾患
- 中皮腫
- 悪性中皮腫
- 肺新生物
- 卵巣腫瘍
- 子宮頸部腫瘍
- トリプルネガティブ乳房腫瘍
- 陰茎新生物
- 複素環化化合物、1リング
- 複素環化化合物
- 無機化学物質
- 塩素化合物
- 窒素化合物
- デオキシシチジン
- シチジン
- ピリミジンヌクレオシド
- ピリミジン
- 要素
- 金属
- 金属、重い
- プラチナ化合物
- 遷移要素
- ゲムシタビン
- シスプラチン
- クエン酸1,2-ジアミノシクロヘキサン白金II
- 白金
- ベイ1895344
その他の研究ID番号
- NCI-2020-05428
- UM1CA186717 (米国 NIH グラント/契約)
- NCI-2020-05428 (レジストリ識別子:CTRP (Clinical Trial Reporting Program))
- PHI-117
- 10404 (その他の識別子:CTEP)
- 10404 (その他の識別子:City of Hope Comprehensive Cancer Center LAO)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。